Skip to main content

Table 4 Systemic therapies after LND. Additional systemic therapies are shown. Only therapies after LND and before occurrence of regional recurrence has been recorded

From: Morbidity and oncologic outcome after saphenous vein-sparing inguinal lymphadenectomy in melanoma patients

   Overall SaphRes SaphSpar p value
Interferone [%] 17.0 21.0 10.5 0.1773
Any chemotherapy [%] 20.0 17.7 23.7 0.4709
 Dacarbazine [%] 17.0 14.5 21.1 0.3983
 Paclitaxel [%] 6.0 6.5 5.3 0.8081
 Cisplatin [%] 4.0 3.2 5.3 0.6138
Vemurafenib [%] 1.0 0.0 2.6 0.1992
Sorafenib [%] 1.0 1.6 0.0 0.4314
Ipilimumab [%] 7.0 6.5 7.9 0.7837
Vaccination [%] 6.0 6.5 5.3 0.8081